- Home
- BPOPM vs VCEL Comparison
BPOPM vs VCEL Comparison
Compare BPOPM & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
BPOPM
Popular Inc. Popular Capital Trust II - 6.125% Cumulative Monthly Income Trust Preferred Securities
Current Price
Company Overview
Basic Information| Metric | BPOPM | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.0B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | BPOPM | VCEL |
|---|---|---|
| Price | $25.37 | $37.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.50 |
| AVG Volume (30 Days) | N/A | ★ 599.1K |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | N/A | $18.55 |
| P/E Ratio | ★ N/A | $152.71 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | N/A | $29.24 |
| 52 Week High | N/A | $63.00 |
Technical Indicators
Market Signals| Indicator | BPOPM | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 57.96 | 52.34 |
| Support Level | $25.00 | $35.53 |
| Resistance Level | $25.48 | $38.15 |
| Average True Range (ATR) | 0.15 | 1.30 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 82.46 | 75.70 |
Price Performance
Historical ComparisonAbout BPOPM Popular Inc. Popular Capital Trust II - 6.125% Cumulative Monthly Income Trust Preferred Securities
Popular Capital Trust II is a statutory trust. It is engaged in issuing capital securities.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.